Phase IV, Single Arm Study of Safety and Efficacy of Everolimus in Chinese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma Not Requiring Immediate Surgery
Phase of Trial: Phase IV
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Everolimus (Primary)
- Indications Angiomyolipoma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 11 Jan 2019 Planned End Date changed from 29 Dec 2021 to 6 Jan 2022.
- 11 Jan 2019 Planned primary completion date changed from 29 Dec 2021 to 6 Jan 2022.
- 02 Dec 2018 Status changed from not yet recruiting to recruiting.